Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
BACKGROUND
The optimal schedule of taxane administration has been an area of active interest in several clinical trials.


METHODS
To evaluate the efficacy and toxicity of carboplatin and weekly paclitaxel combination chemotherapy, a phase II study was conducted for chemo-naïve, advanced non-small cell lung cancer (NSCLC) patients. Patients received paclitaxel 100 mg/m2 on days 1, 8 and 15, and carboplatin with the target dose of area under the curve of 6 on day 1 every 28 days.


RESULTS
Forty patients were enrolled. Overall response rate and survival at one year by intent-to-treat analyses was 35% and 57.5%, respectively. The median survival time was 12.2 months. Twenty-two patients (56%) had grade 3 or greater neutropenia. Grade 3 sensory and motor neuropathy were seen in one patient (3%).


CONCLUSIONS
Carboplatin and weekly paclitaxel combination chemotherapy is an active and feasible regimen for patients with advanced NSCLC.
Nakadate
Megumi
M
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Yamazaki
Koichi
K
Konishi
Jun
J
Kinoshita
Ichiro
I
Sukoh
Noriaki
N
Harada
Masao
M
Akie
Kenji
K
Ogura
Shigeaki
S
Ishida
Takashi
T
Munakata
Mitsuru
M
Dosaka-Akita
Hirotoshi
H
Isobe
Hiroshi
H
Nishimura
Masaharu
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D016019:Survival Analysis; D016896:Treatment Outcome
D016190:Carboplatin; D017239:Paclitaxel